Basic Description

Synonyms	DAUNORUBICIN HYDROCHLORIDE \| DAUNORUBICIN HCL \| Daunomycin hydrochloride \| Cerubidine \| Daunomycin chlorohydrate \| RP-13057 Hydrochloride \| Daunomycin, hydrochloride \| Daunoblastina \| RP 13057 hydrochloride \| Rubidomycin hydrochloride \| Daunomycin HCL \| O
Specifications & Purity	≥90%
Biochemical and Physiological Mechanisms	Daunorubicin hydrochloride is a DNA intercalating anthracylcine natural product isolated from Streptomyces peucetius. Upon intercalation, Daunorubicin forms stable complexes with the DNA backbone, inhibiting normal functioning of the double helix and the
Storage Temp	Store at -20°C,Argon charged
Shipped In	Ice chest + Ice pads
Action Type	INHIBITOR
Mechanism of action	DNA inhibitor
Note	Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
Product Description	Daunorubicin HCl inhibits both DNA and RNA synthesis and inhibits DNA synthesis with Ki of 0.02 μM. A DNA intercalator which may suppress acute leukemia proliferation

Associated Targets(Human)

S100A4 Tchem Protein S100-A4 (1 Activities)

Discover Target: S100A4

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

ESR1 Tclin Estrogen receptor alpha (17718 Activities)

Discover Target: ESR1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

NR3C1 Tclin Glucocorticoid receptor (14987 Activities)

Discover Target: NR3C1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

AR Tclin Androgen Receptor (11781 Activities)

Discover Target: AR

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

VDR Tclin Vitamin D receptor (26531 Activities)

Discover Target: VDR

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

TSHR Tclin Thyroid stimulating hormone receptor (29986 Activities)

Discover Target: TSHR

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

ACHE Tclin Acetylcholinesterase (18204 Activities)

Discover Target: ACHE

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

PPARG Tclin Peroxisome proliferator-activated receptor gamma (15191 Activities)

Discover Target: PPARG

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

TNF Tclin TNF-alpha (1897 Activities)

Discover Target: TNF

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

THRB Tclin Thyroid hormone receptor beta-1 (7926 Activities)

Discover Target: THRB

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

RXRA Tclin Retinoid X receptor alpha (3637 Activities)

Discover Target: RXRA

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CXCL8 Tchem Interleukin-8 (642 Activities)

Discover Target: CXCL8

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

POLB Tchem DNA polymerase beta (23632 Activities)

Discover Target: POLB

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

AHR Tclin Aryl hydrocarbon receptor (1071 Activities)

Discover Target: AHR

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

PLK1 Tchem Serine/threonine-protein kinase PLK1 (28605 Activities)

Discover Target: PLK1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

NFKB1 Tclin Nuclear factor NF-kappa-B p105 subunit (1459 Activities)

Discover Target: NFKB1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

GLP1R Tclin Glucagon-like peptide 1 receptor (111429 Activities)

Discover Target: GLP1R

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

PIN1 Tchem Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (36611 Activities)

Discover Target: PIN1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

FPR1 Tchem Formyl peptide receptor 1 (1372 Activities)

Discover Target: FPR1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CYP3A4 Tclin Cytochrome P450 3A4 (53859 Activities)

Discover Target: CYP3A4

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

TP53 Tchem Cellular tumor antigen p53 (48468 Activities)

Discover Target: TP53

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

A204 (242 Activities)

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

A498 (42825 Activities)

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CAPAN-1 (772 Activities)

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

EVSA-T (142 Activities)

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

HL-60 (67320 Activities)

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

HT-29 (80576 Activities)

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

K562 (73714 Activities)

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

MCF7 (126967 Activities)

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

MOLT-4 (49676 Activities)

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

NHDF (1164 Activities)

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

OVCAR-3 (48710 Activities)

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

PC-3 (62116 Activities)

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

SK-MEL-28 (48833 Activities)

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

T-24 (2342 Activities)

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

UCLA P-3 (10 Activities)

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

HCT-116 (91556 Activities)

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

HEK293 (82097 Activities)

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

HMEC (560 Activities)

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

WiDr (1835 Activities)

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

HepG2 (196354 Activities)

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

IGROV-1 (47897 Activities)

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

IGR-37 cell line (15 Activities)

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

LNCaP (8286 Activities)

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Lymphoblastoid cell (5959 Activities)

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

M19-MEL (15326 Activities)

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

HeLa (62764 Activities)

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

MDA-MB-231 (73002 Activities)

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

SW-620 (52400 Activities)

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

FEN1 Tchem Flap endonuclease 1 (12055 Activities)

Discover Target: FEN1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

HIF1A Tchem Hypoxia-inducible factor 1 alpha (6027 Activities)

Discover Target: HIF1A

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Associated Targets(non-human)

Ppard Peroxisome proliferator-activated receptor delta (358 Activities)

Discover Target: Ppard

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Mapk1 MAP kinase ERK2 (650 Activities)

Discover Target: Mapk1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Salmonella typhimurium (15756 Activities)

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Plasmodium falciparum (966862 Activities)

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Mus musculus (284745 Activities)

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Rattus norvegicus (775804 Activities)

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CHO (4503 Activities)

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

L1210 (27553 Activities)

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

P388 (20296 Activities)

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

M109 (194 Activities)

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Calf thymus DNA (4845 Activities)

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Salmon testes DNA (254 Activities)

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

lef Anthrax lethal factor (7585 Activities)

Discover Target: lef

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Npsr1 Neuropeptide S receptor (260 Activities)

Discover Target: Npsr1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Luciferin 4-monooxygenase (66902 Activities)

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

rep Replicase polyprotein 1ab (378 Activities)

Discover Target: rep

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

BCHE Cholinesterase (8742 Activities)

Discover Target: BCHE

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Mapt Microtubule-associated protein tau (6 Activities)

Discover Target: Mapt

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Nfe2l2 Nuclear factor erythroid 2-related factor 2 (214 Activities)

Discover Target: Nfe2l2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Rorc Nuclear receptor ROR-gamma (89407 Activities)

Discover Target: Rorc

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

fba Putative fructose-1,6-bisphosphate aldolase (15559 Activities)

Discover Target: fba

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Impa1 Inositol monophosphatase 1 (16203 Activities)

Discover Target: Impa1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

ffp 4'-phosphopantetheinyl transferase ffp (24982 Activities)

Discover Target: ffp

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

FTL Ferritin light chain (43324 Activities)

Discover Target: FTL

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

NS1 Nonstructural protein 1 (33327 Activities)

Discover Target: NS1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

ORF 73 (309 Activities)

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

rpoB Bacterial DNA-directed RNA polymerase (88 Activities)

Discover Target: rpoB

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

SARS-CoV-2 (38078 Activities)

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Names and Identifiers

Pubchem Sid	488183611
Pubchem Sid Url	https://pubchem.ncbi.nlm.nih.gov/substance/488183611
IUPAC Name	(7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride
INCHI	InChI=1S/C27H29NO10.ClH/c1-10-22(30)14(28)7-17(37-10)38-16-9-27(35,11(2)29)8-13-19(16)26(34)21-20(24(13)32)23(31)12-5-4-6-15(36-3)18(12)25(21)33;/h4-6,10,14,16-17,22,30,32,34-35H,7-9,28H2,1-3H3;1H/t10-,14-,16-,17-,22+,27-;/m0./s1
InChi Key	GUGHGUXZJWAIAS-QQYBVWGSSA-N
Canonical SMILES	Cl.COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O
Isomeric SMILES	C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O.Cl
WGK Germany	3
RTECS	HB7878000
Alternate CAS	20830-81-3
PubChem CID	62770
UN Number	2811
Packing Group	I
Molecular Weight	563.98
Beilstein	4229221

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

12 results found

Lot Number	Certificate Type	Date	Item
F2428225	Certificate of Analysis	Jun 03, 2024	D122335
F2428226	Certificate of Analysis	Jun 03, 2024	D122335
F2428227	Certificate of Analysis	Jun 03, 2024	D122335
F2428228	Certificate of Analysis	Jun 03, 2024	D122335
C2308992	Certificate of Analysis	Dec 17, 2022	D122335
C2308993	Certificate of Analysis	Dec 17, 2022	D122335
C2308994	Certificate of Analysis	Dec 17, 2022	D122335
C2308995	Certificate of Analysis	Dec 17, 2022	D122335
C2308996	Certificate of Analysis	Dec 17, 2022	D122335
C2308997	Certificate of Analysis	Dec 17, 2022	D122335
C2308998	Certificate of Analysis	Dec 17, 2022	D122335
K2210228	Certificate of Analysis	Sep 06, 2021	D122335

Chemical and Physical Properties

Solubility	Soluble in water (≥113), methanol, ethanol (≥10), and DMSO (≥72 mg/mL).
Sensitivity	Moisture & heat sensitive.light sensitive
Specific Rotation[α]	260°
Melt Point(°C)	167 °C

Safety and Hazards(GHS)

Pictogram(s)	GHS06, GHS08, GHS07
Signal	Danger
Hazard Statements	H301:Toxic if swallowed H341:Suspected of causing genetic defects H351:Suspected of causing cancer H302:Harmful if swallowed H334:May cause allergy or asthma symptoms or breathing difficulties if inhaled H360:May damage fertility or the unborn child
Precautionary Statements	P261:Avoid breathing dust/fume/gas/mist/vapors/spray. P280:Wear protective gloves/protective clothing/eye protection/face protection. P321:Specific treatment (see ... on this label). P405:Store locked up. P501:Dispose of contents/container to ... P264:Wash hands [and …] thoroughly after handling. P284:[In case of inadequate ventilation] Wear respiratory protection. P281:Use personal protective equipment as required. P270:Do not eat, drink or smoke when using this product. P304+P340:IF INHALED: Remove person to fresh air and keep comfortable for breathing. P330:Rinse mouth. P203:Obtain, read and follow all safety instructions before use. P301+P316:IF SWALLOWED: Get emergency medical help immediately. P301+P317:IF SWALLOWED: Get medical help. P318:if exposed or concerned, get medical advice. P342+P316:If experiencing respiratory symptoms: Get emergence medical help immediately.
WGK Germany	3
RTECS	HB7878000
Class	6.1
Merck Index	2832

Alternative Products

FAQs and Articles

FAQ

Antibody-drug Conjugates: A Comprehensive Guide

Categories: Technical articles

Tags:

Biomedical materials tumor cell Antibody drug conjugates

Citations of This Product

1. Jiezhou Pan, Haotian Liao, Guidong Gong, Yunxiang He, Qin Wang, Lang Qin, Yaoyao Zhang, Hirotaka Ejima, Blaise L. Tardy, Joseph J. Richardson, Jiaojiao Shang, Orlando J. Rojas, Yong Zeng, Junling Guo. (2023) Supramolecular nanoarchitectonics of phenolic-based nanofiller for controlled diffusion of versatile drugs in hydrogels. JOURNAL OF CONTROLLED RELEASE, 360 (433). [PMID:37422124]
2. Bo Fu, Can Tao, Nian Chen, Jie-Rou Lin, Ping Zhao. (2021) ZnO QD covalently coated, GSH/pH dual-responsive drug delivery system for chemotherapeutic/ionic synergistic therapy. JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 66 (102908). [PMID:]

References

1. Pengcheng Shi,Jie Zha,Xutao Guo,Feili Chen,Zhiping Fan,Fen Huang,Fanyi Meng,Xiaoli Liu,Ru Feng,Bing Xu. (2012-12-21) Idarubicin is superior to daunorubicin in remission induction of de novo acute myeloid leukemia patients with high MDR1 expression.. Pharmacogenomics, 14 ((1)): (17-23). [PMID:23252945]
2. Tereza Hartmanová,Vojtěch Tambor,Juraj Lenčo,Claudia A Staab-Weijnitz,Edmund Maser,Vladimír Wsól. (2013-01-09) S-nitrosoglutathione covalently modifies cysteine residues of human carbonyl reductase 1 and affects its activity.. Chemico-biological interactions, 202 ((1-3)): (136-145). [PMID:23295225]
3. Mingjuan Liu,Ji Liu,Lihui Liu,Li Yu,Bing Shi,Liping Ye,Yongqing Zhang,Hu Chen. (2013-01-09) A case report of acute myeloid leukemia after liver transplantation.. Acta haematologica, 129 ((4)): (225-228). [PMID:23295767]
4. Pranjal Chandra,Hui-Bog Noh,Yoon-Bo Shim. (2013-01-09) Cancer cell detection based on the interaction between an anticancer drug and cell membrane components.. Chemical communications (Cambridge, England), 49 ((19)): (1900-1902). [PMID:23296144]
5. Utz Krug,Anja Koschmieder,Daniela Schwammbach,Joachim Gerss,Nicola Tidow,Björn Steffen,Gesine Bug,Christian H Brandts,Markus Schaich,Christoph Röllig,Christian Thiede,Richard Noppeney,Matthias Stelljes,Thomas Büchner,Steffen Koschmieder,Ulrich Dührsen,Hubert Serve,Gerhard Ehninger,Wolfgang E Berdel,Carsten Müller-Tidow. (2013-01-10) Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia--a randomised SAL pilot study.. PloS one, 7 ((12)): (e52695-e52695). [PMID:23300745]
6. Gertjan J L Kaspers,Martin Zimmermann,Dirk Reinhardt,Brenda E S Gibson,Rienk Y J Tamminga,Olga Aleinikova,Hortensia Armendariz,Michael Dworzak,Shau-Yin Ha,Henrik Hasle,Liisa Hovi,Alexei Maschan,Yves Bertrand,Guy G Leverger,Bassem I Razzouk,Carmelo Rizzari,Petr Smisek,Owen Smith,Batia Stark,Ursula Creutzig. (2013-01-16) Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 ((5)): (599-607). [PMID:23319696]
7. S Park,N Chapuis,F Saint Marcoux,C Recher,T Prebet,P Chevallier,J-Y Cahn,T Leguay,P Bories,F Witz,T Lamy,P Mayeux,C Lacombe,C Demur,J Tamburini,A Merlat,R Delepine,N Vey,F Dreyfus,M C Béné,N Ifrah,D Bouscary. (2013-01-17) A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse.. Leukemia, 27 ((7)): (1479-1486). [PMID:23321953]
8. Rocky Pramanik,Xia Sheng,Brian Ichihara,Nora Heisterkamp,Steven D Mittelman. (2013-01-22) Adipose tissue attracts and protects acute lymphoblastic leukemia cells from chemotherapy.. Leukemia research, 37 ((5)): (503-509). [PMID:23332453]
9. Mona Hassanein,Eshetu G Atenafu,Andre C Schuh,Karen W L Yee,Mark D Minden,Aaron D Schimmer,Vikas Gupta,Joseph M Brandwein. (2013-01-30) High-dose cytarabine-based consolidation shows superior results for older AML patients with intermediate risk cytogenetics in first complete remission.. Leukemia research, 37 ((5)): (556-560). [PMID:23357460]
10. Sarah Bertoli,Emilie Bérard,Françoise Huguet,Anne Huynh,Suzanne Tavitian,François Vergez,Sophie Dobbelstein,Nicole Dastugue,Véronique Mansat-De Mas,Eric Delabesse,Eliane Duchayne,Cécile Demur,Audrey Sarry,Valérie Lauwers-Cances,Guy Laurent,Michel Attal,Christian Récher. (2013-02-01) Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia.. Blood, 121 ((14)): (2618-2626). [PMID:23365464]
11. Oliver Teuffel,Kurt Leibundgut,Thomas Lehrnbecher,Todd A Alonzo,Joseph Beyene,Lillian Sung. (2013-02-13) Anthracyclines during induction therapy in acute myeloid leukaemia: a systematic review and meta-analysis.. British journal of haematology, 161 ((2)): (192-203). [PMID:23398482]
12. G M Marshall,L Dalla Pozza,R Sutton,A Ng,H A de Groot-Kruseman,V H van der Velden,N C Venn,H van den Berg,E S J M de Bont,R Maarten Egeler,P M Hoogerbrugge,G J L Kaspers,M B Bierings,E van der Schoot,J van Dongen,T Law,S Cross,H Mueller,V de Haas,M Haber,T Révész,F Alvaro,R Suppiah,M D Norris,R Pieters. (2013-02-15) High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation.. Leukemia, 27 ((7)): (1497-1503). [PMID:23407458]
13. Marko Kavcic,Brian T Fisher,Yimei Li,Alix E Seif,Kari Torp,Dana M Walker,Yuan-Shung Huang,Grace E Lee,Sarah K Tasian,Marijana Vujkovic,Rochelle Bagatell,Richard Aplenc. (2013-02-26) Induction mortality and resource utilization in children treated for acute myeloid leukemia at free-standing pediatric hospitals in the United States.. Cancer, 119 ((10)): (1916-1923). [PMID:23436301]
14. Richard M Stone. (2013-02-27) Acute myeloid leukemia in first remission: to choose transplantation or not?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 ((10)): (1262-1266). [PMID:23439752]
15. Nobuhiro Hiramoto,Yukio Kobayashi,Junko Nomoto,Dai Maruyama,Takashi Watanabe,Naobumi Tochigi,Koh Furuta,Ken Takeda,Hirokazu Chuman,Shigeki Yagyu,Hajime Hosoi,Kensei Tobinai. (2013-03-12) Ewing sarcoma arising after treatment of diffuse large B-cell lymphoma.. Japanese journal of clinical oncology, 43 ((4)): (417-421). [PMID:23475435]
16. Lili Xiang,Man Li,Yan Liu,Jiangnong Cen,Zixing Chen,Xiao Zhen,Xiaobao Xie,Xiangshan Cao,Weiying Gu. (2013-03-22) The clinical characteristics and prognostic significance of MN1 gene and MN1-associated microRNA expression in adult patients with de novo acute myeloid leukemia.. Annals of hematology, 92 ((8)): (1063-1069). [PMID:23515710]
17. Benjamin Doughty,Yi Rao,Samuel W Kazer,Sheldon J J Kwok,Nicholas J Turro,Kenneth B Eisenthal. (2013-03-27) Probing the relative orientation of molecules bound to DNA through controlled interference using second-harmonic generation.. Proceedings of the National Academy of Sciences of the United States of America, 110 ((15)): (5756-5758). [PMID:23530200]
18. Weiwei Jiang,Bin Li,Xinchuan Zheng,Xin Liu,Xichun Pan,Rongxin Qing,Yanyan Cen,Jiang Zheng,Hong Zhou. (2013-04-04) Artesunate has its enhancement on antibacterial activity of β-lactams via increasing the antibiotic accumulation within methicillin-resistant Staphylococcus aureus (MRSA).. The Journal of antibiotics, 66 ((6)): (339-345). [PMID:23549351]
19. Sang Min Lee,Won Sik Lee,Ho Jin Shin,Je-Jung Lee,Sang Kyun Sohn,Joon Ho Moon,Hyeon Seok Eom,Jong Ho Won,Kyoo-Hyung Lee,Je-Hwan Lee,Dae-Young Kim,Sung-Soo Yoon,Inho Kim,Chul Won Jung,Seok Jin Kim,Hawk Kim,Jae Hoon Lee,Hun-Mo Ryoo,Gyeong-Won Lee,Sung-Hyun Kim,Yeung-Chul Mun,Min Kyoung Kim,Young Don Joo. (2013-04-06) Escalated daunorubicin dosing as an induction treatment for Philadelphia-negative adult acute lymphoblastic leukemia.. Annals of hematology, 92 ((8)): (1101-1110). [PMID:23558905]
20. Ursula Creutzig,Martin Zimmermann,Jean-Pierre Bourquin,Michael N Dworzak,Gudrun Fleischhack,Norbert Graf,Thomas Klingebiel,Bernhard Kremens,Thomas Lehrnbecher,Christine von Neuhoff,Jörg Ritter,Annette Sander,André Schrauder,Arend von Stackelberg,Jan Starý,Dirk Reinhardt. (2013-05-25) Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004.. Blood, 122 ((1)): (37-43). [PMID:23704089]
21. Abhi Das,Gopinatha Suresh Kumar. (2013-06-19) Binding of the plant alkaloid aristololactam-β-d-glucoside and antitumor antibiotic daunomycin to single stranded polyribonucleotides.. Biochimica et biophysica acta, 1830 ((10)): (4708-4718). [PMID:23769768]
22. Eduard Jirkovský,Olga Lenčová-Popelová,Miloš Hroch,Michaela Adamcová,Yvona Mazurová,Jaroslava Vávrová,Stanislav Mičuda,Tomáš Šimůnek,Vladimír Geršl,Martin Štěrba. (2013-07-09) Early and delayed cardioprotective intervention with dexrazoxane each show different potential for prevention of chronic anthracycline cardiotoxicity in rabbits.. Toxicology, 311 ((3)): (191-204). [PMID:23831762]
23. Cedric Dos Santos,Tinisha McDonald,Yin Wei Ho,Hongjun Liu,Allen Lin,Stephen J Forman,Ya-Huei Kuo,Ravi Bhatia. (2013-07-31) The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents.. Blood, 122 ((11)): (1900-1913). [PMID:23896410]
24. S Singh-Rambiritch,N H Wood. (2013-08-21) Post-chemotherapeutic resolution of acute myeloid leukaemia-induced gingival enlargement: a case report.. SADJ : journal of the South African Dental Association = tydskrif van die Suid-Afrikaanse Tandheelkundige Vereniging, 67 ((7)): (344-347). [PMID:23951790]
25. Hiroaki Shimizu,Takayuki Saitoh,Nahoko Hatsumi,Satoru Takada,Hiroshi Handa,Takahiro Jimbo,Toru Sakura,Shuichi Miyawaki,Yoshihisa Nojima. (2013-09-24) Prevalence of extramedullary relapses is higher after allogeneic stem cell transplantation than after chemotherapy in adult patients with acute myeloid leukemia.. Leukemia research, 37 ((11)): (1477-1481). [PMID:24054717]
26. Marta Stojak,Lidia Mazur,Malgorzata Opydo-Chanek,Malgorzata Lukawska,Irena Oszczapowicz. (2013-10-15) In vitro induction of apoptosis and necrosis by new derivatives of daunorubicin.. Anticancer research, 33 ((10)): (4439-4443). [PMID:24123013]
27. Haisheng Peng,Dan Du,Jinqiu Zhang. (2013-12-07) Liposomes modified with p-aminophenyl-α-D-mannopyranoside: a promising delivery system in targeting the brain.. Therapeutic delivery, 4 ((12)): (1475-1477). [PMID:24304243]
28. Yi-Yang Chen,Cih-En Huang,Hui-Ju Chou,Pei-Shan Tsai,Chang-Hsien Lu,Miao-Fen Chen,Kuan-Der Lee,Ping-Tsung Chen,Jrhau Lung,Chih-Cheng Chen. (2013-12-18) Mutant DNMT3A clone evading chemotherapy and infiltrating central nervous system in a patient with molecularly good-risk acute myeloid leukemia.. Annals of hematology, 93 ((8)): (1441-1442). [PMID:24337413]
29. Sarah A Buckley,Megan Othus,Vladimir Vainstein,Janis L Abkowitz,Elihu H Estey,Roland B Walter. (2014-01-03) Prediction of adverse events during intensive induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromes.. American journal of hematology, 89 ((4)): (423-428). [PMID:24382796]
30. Steven E Coutre,Megan Othus,Bayard Powell,Cheryl L Willman,Wendy Stock,Elisabeth Paietta,Denise Levitan,Meir Wetzler,Eyal C Attar,Jessica K Altman,Steven D Gore,Tracy Maher,Kenneth J Kopecky,Martin S Tallman,Richard A Larson,Frederick R Appelbaum. (2014-02-18) Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy.. British journal of haematology, 165 ((4)): (497-503). [PMID:24528179]
31. Yanyan Mei,Chao Gao,Kailing Wang,Lei Cui,Weijing Li,Xiaoxi Zhao,Feifei Liu,Minyuan Wu,Guoren Deng,Wei Ding,Hongti Jia,Zhigang Li. (2014-04-12) Effect of microRNA-210 on prognosis and response to chemotherapeutic drugs in pediatric acute lymphoblastic leukemia.. Cancer science, 105 ((4)): (463-472). [PMID:24720529]
32. Jakub Hofman,Beata Malcekova,Adam Skarka,Eva Novotna,Vladimir Wsol. (2014-05-17) Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3.. Toxicology and applied pharmacology, 278 ((3)): (238-248). [PMID:24832494]
33. Jessica L Heath,Shelly E Burgett,Ana M Gaca,Ronald Jaffe,Daniel S Wechsler. (2014-06-04) Successful treatment of pediatric histiocytic sarcoma using abbreviated high-risk leukemia chemotherapy.. Pediatric blood & cancer, 61 ((10)): (1874-1876). [PMID:24888336]
34. Petr Kosztyu,Romana Bukvova,Petr Dolezel,Petr Mlejnek. (2014-06-24) Resistance to daunorubicin, imatinib, or nilotinib depends on expression levels of ABCB1 and ABCG2 in human leukemia cells.. Chemico-biological interactions, 219 (203-210). [PMID:24954033]
35. Caroline Damico Candido,Michel Leandro Campos,Juliana Uruguay Correa Vidigal Assumpção,Kelly Chrystina Pestana,Elias Carvalho Padilha,Iracilda Zeppone Carlos,Rosângela Gonçalves Peccinini. (2014-08-08) Biocompatible microemulsion modifies the tissue distribution of doxorubicin.. Journal of pharmaceutical sciences, 103 ((10)): (3297-3301). [PMID:25100266]
36. Hernan Carol,Mannie M Y Fan,Troy O Harasym,Ingrid Boehm,Lawrence D Mayer,Peter Houghton,Malcolm A Smith,Richard B Lock. (2014-09-10) Efficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program.. Pediatric blood & cancer, 62 ((1)): (65-71). [PMID:25203866]
37. Jorge E Cortes,Stuart L Goldberg,Eric J Feldman,David A Rizzeri,Donna E Hogge,Melissa Larson,Arnaud Pigneux,Christian Recher,Gary Schiller,Krzysztof Warzocha,Hagop Kantarjian,Arthur C Louie,Jonathan E Kolitz. (2014-09-17) Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.. Cancer, 121 ((2)): (234-242). [PMID:25223583]
38. Takuya Suzuki,Masako Ichihara,Kenji Hyodo,Eiichi Yamamoto,Tatsuhiro Ishida,Hiroshi Kiwada,Hiroshi Kikuchi,Hiroshi Ishihara. (2014-10-05) Influence of dose and animal species on accelerated blood clearance of PEGylated liposomal doxorubicin.. International journal of pharmaceutics, 476 ((1-2)): (205-212). [PMID:25280884]
39. Luca Maurillo,Francesco Buccisano,Alfonso Piciocchi,Maria Ilaria Del Principe,Chiara Sarlo,Ambra Di Veroli,Paola Panetta,Maria Irno-Consalvo,Daniela Nasso,Concetta Ditto,Marco Refrigeri,Gottardo De Angelis,Raffaella Cerretti,William Arcese,Giuseppe Sconocchia,Francesco Lo-Coco,Sergio Amadori,Adriano Venditti. (2014-11-08) Minimal residual disease as biomarker for optimal biologic dosing of ARA-C in patients with acute myeloid leukemia.. American journal of hematology, 90 ((2)): (125-131). [PMID:25377359]
40. Tomasz Wojcik,Elzbieta Buczek,Katarzyna Majzner,Agnieszka Kolodziejczyk,Justyna Miszczyk,Patrycja Kaczara,Wojciech Kwiatek,Malgorzata Baranska,Marek Szymonski,Stefan Chlopicki. (2014-12-23) Comparative endothelial profiling of doxorubicin and daunorubicin in cultured endothelial cells.. Toxicology in vitro : an international journal published in association with BIBRA, 29 ((3)): (512-521). [PMID:25529801]
41. Daniel C Ferguson,Qiuying Cheng,Javier G Blanco. (2015-04-29) Characterization of the Canine Anthracycline-Metabolizing Enzyme Carbonyl Reductase 1 (cbr1) and the Functional Isoform cbr1 V218.. Drug metabolism and disposition: the biological fate of chemicals, 43 ((7)): (922-927). [PMID:25918240]
42. Andrea R Beyer,Lauren VieBrock,Kyle G Rodino,Daniel P Miller,Brittney K Tegels,Richard T Marconi,Jason A Carlyon. (2015-07-15) Orientia tsutsugamushi Strain Ikeda Ankyrin Repeat-Containing Proteins Recruit SCF1 Ubiquitin Ligase Machinery via Poxvirus-Like F-Box Motifs.. Journal of bacteriology, 197 ((19)): (3097-3109). [PMID:26170417]
43. Siyam M Ansar,Thilak Mudalige. (2019-12-06) Characterization of doxorubicin liposomal formulations for size-based distribution of drug and excipients using asymmetric-flow field-flow fractionation (AF4) and liquid chromatography-mass spectrometry (LC-MS).. International journal of pharmaceutics, 574 (118906-118906). [PMID:31805309]
44. Cristina Morales Torres,Mary Y Wu,Sebastijan Hobor,Elanor N Wainwright,Matthew J Martin,Harshil Patel,William Grey,Eva Grönroos,Steven Howell,Joana Carvalho,Ambrosius P Snijders,Michael Bustin,Dominique Bonnet,Paul D Smith,Charles Swanton,Michael Howell,Paola Scaffidi. (2020-04-15) Selective inhibition of cancer cell self-renewal through a Quisinostat-histone H1.0 axis.. Nature communications, 11 ((1)): (1792-1792). [PMID:32286289]
45. Mamta Amrute-Nayak,Gloria Pegoli,Tim Holler,Alfredo Jesus Lopez-Davila,Chiara Lanzuolo,Arnab Nayak. (2020-12-12) Chemotherapy triggers cachexia by deregulating synergetic function of histone-modifying enzymes.. Journal of cachexia, sarcopenia and muscle, 12 ((1)): (159-176). [PMID:33305533]
46. Jay Chhablani,Alejandra Nieto,Huiyuan Hou,Elizabeth C Wu,William R Freeman,Michael J Sailor,Lingyun Cheng. (2013-01-17) Oxidized porous silicon particles covalently grafted with daunorubicin as a sustained intraocular drug delivery system.. Investigative ophthalmology & visual science, 54 ((2)): (1268-1279). [PMID:23322571]
47. Qian Ding,Ran Gu,Jiayi Liang,Xiangzhong Zhang,Yunxian Chen. (2013-01-22) PI-103 sensitizes acute myeloid leukemia stem cells to daunorubicin-induced cytotoxicity.. Medical oncology (Northwood, London, England), 30 ((1)): (395-395). [PMID:23335068]
48. Ishrat Jabeen,Penpun Wetwitayaklung,Peter Chiba,Manuel Pastor,Gerhard F Ecker. (2013-02-13) 2D- and 3D-QSAR studies of a series of benzopyranes and benzopyrano[3,4b][1,4]-oxazines as inhibitors of the multidrug transporter P-glycoprotein.. Journal of computer-aided molecular design, 27 ((2)): (161-171). [PMID:23400406]
49. Anna Rommer,Birgit Steinmetz,Friederike Herbst,Hubert Hackl,Petra Heffeter,Daniela Heilos,Martin Filipits,Katarina Steinleitner,Shayda Hemmati,Irene Herbacek,Ilse Schwarzinger,Katharina Hartl,Pieter Rondou,Hanno Glimm,Kadin Karakaya,Alwin Krämer,Walter Berger,Rotraud Wieser. (2013-03-05) EVI1 inhibits apoptosis induced by antileukemic drugs via upregulation of CDKN1A/p21/WAF in human myeloid cells.. PloS one, 8 ((2)): (e56308-e56308). [PMID:23457546]
50. Stephen H Petersdorf,Kenneth J Kopecky,Marilyn Slovak,Cheryl Willman,Thomas Nevill,Joseph Brandwein,Richard A Larson,Harry P Erba,Patrick J Stiff,Robert K Stuart,Roland B Walter,Martin S Tallman,Leif Stenke,Frederick R Appelbaum. (2013-04-18) A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia.. Blood, 121 ((24)): (4854-4860). [PMID:23591789]
51. Jae-Ho Yoon,Byung-Sik Cho,Hee-Je Kim,Jung-Ho Kim,Seung-Hwan Shin,Seung-Ah Yahng,Sung-Eun Lee,Ki-Seong Eom,Yoo-Jin Kim,Seok Lee,Chang-Ki Min,Seok-Goo Cho,Dong-Wook Kim,Jong-Wook Lee,Woo-Sung Min,Chong-Won Park. (2013-08-29) Outcomes of elderly de novo acute myeloid leukemia treated by a risk-adapted approach based on age, comorbidity, and performance status.. American journal of hematology, 88 ((12)): (1074-1081). [PMID:23983148]
52. Carlos E Vigil,Wei Tan,George Deeb,Sheila N Sait,Annemarie W Block,Petr Starostik,Elizabeth A Griffiths,James E Thompson,Jessica D Greene,Laurie A Ford,Eunice S Wang,Meir Wetzler. (2013-09-10) Phase II trial of clofarabine and daunorubicin as induction therapy for acute myeloid leukemia patients greater than or equal to 60 years of age.. Leukemia research, 37 ((11)): (1468-1471). [PMID:24011826]
53. Robert S Nickel,Frank Keller,John Bergsagel,Todd Cooper,Marla Daves,Himalee Sabnis,Glen Lew. (2013-12-21) Mitoxantrone as a substitute for daunorubicin during induction in newly diagnosed lymphoblastic leukemia and lymphoma.. Pediatric blood & cancer, 61 ((5)): (810-814). [PMID:24357218]
54. Sylvain Pilorge,Sophie Rigaudeau,Florence Rabian,Clémentine Sarkozy,Anne L Taksin,Hassan Farhat,Fathia Merabet,Stéphanie Ghez,Victoria Raggueneau,Christine Terré,Isabelle Garcia,Aline Renneville,Claude Preudhomme,Sylvie Castaigne,Philippe Rousselot. (2014-01-01) Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse.. American journal of hematology, 89 ((4)): (399-403). [PMID:24375467]
55. Antonio R Lucena-Araujo,Haesook T Kim,Rafael H Jacomo,Raul A Melo,Rosane Bittencourt,Ricardo Pasquini,Katia Pagnano,Evandro M Fagundes,Maria de Lourdes Chauffaille,Carlos S Chiattone,Ana Silvia Lima,Guillermo Ruiz-Argüelles,Maria Soledad Undurraga,Lem Martinez,Hau C Kwaan,Robert Gallagher,Charlotte M Niemeyer,Stanley L Schrier,Martin S Tallman,David Grimwade,Arnold Ganser,Nancy Berliner,Raul C Ribeiro,Francesco Lo-Coco,Bob Löwenberg,Miguel A Sanz,Eduardo M Rego. (2014-07-02) Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study.. Annals of hematology, 93 ((12)): (2001-2010). [PMID:24981688]
56. Enrico De Astis,Marino Clavio,Anna Maria Raiola,Anna Ghiso,Fabio Guolo,Paola Minetto,Federica Galaverna,Maurizio Miglino,Carmen Di Grazia,Filippo Ballerini,Carlo Marani,Giordana Pastori,Laura Mitscheunig,Fabio Cruciani,Davide Lovera,Riccardo Varaldo,Chiara Ghiggi,Roberto Massimo Lemoli,Andrea Bacigalupo,Marco Gobbi. (2014-07-06) Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.. Annals of hematology, 93 ((12)): (2011-2018). [PMID:24989345]
57. Jiezhou Pan, Haotian Liao, Guidong Gong, Yunxiang He, Qin Wang, Lang Qin, Yaoyao Zhang, Hirotaka Ejima, Blaise L. Tardy, Joseph J. Richardson, Jiaojiao Shang, Orlando J. Rojas, Yong Zeng, Junling Guo. (2023) Supramolecular nanoarchitectonics of phenolic-based nanofiller for controlled diffusion of versatile drugs in hydrogels. JOURNAL OF CONTROLLED RELEASE, 360 (433). [PMID:37422124]
58. Bo Fu, Can Tao, Nian Chen, Jie-Rou Lin, Ping Zhao. (2021) ZnO QD covalently coated, GSH/pH dual-responsive drug delivery system for chemotherapeutic/ionic synergistic therapy. JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 66 (102908). [PMID:]

Solution Calculators

Molarity Calculator

Determine the necessary mass, volume, or concentration for preparing a solution.

Dilution Calculator

Determine the dilution needed to prepare a stock solution.

SKU	Size	Availability	Price
D122335-10mg	10mg	In stock	$9.90
D122335-50mg	50mg	In stock	$19.90
D122335-250mg	250mg	In stock	$49.90
D122335-1g	1g	In stock	$139.90

Daunorubicin hydrochloride - >90%, high purity , DNA inhibitor, CAS No.23541-50-6, DNA inhibitor